# Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus

> **NCT01603121** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eastern Virginia Medical School** · enrollment: 1 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Lisofylline

## Key facts

- **NCT ID:** NCT01603121
- **Lead sponsor:** Eastern Virginia Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Unable to enroll sufficient number of subjects
- **Last updated:** 2016-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603121, "Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01603121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*